News headlines about The Joint Corp. (NASDAQ:JYNT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Joint Corp. earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.676148750034 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
The Joint Corp. (NASDAQ JYNT) traded down 1.93% during mid-day trading on Wednesday, reaching $4.58. The company’s stock had a trading volume of 12,832 shares. The firm’s market capitalization is $60.36 million. The firm’s 50 day moving average price is $4.71 and its 200 day moving average price is $4.07. The Joint Corp. has a 52 week low of $1.96 and a 52 week high of $5.09.
The Joint Corp. (NASDAQ:JYNT) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $6.02 million during the quarter, compared to analyst estimates of $5.76 million. The Joint Corp. had a negative return on equity of 103.25% and a negative net margin of 48.08%. On average, analysts anticipate that The Joint Corp. will post ($0.33) EPS for the current fiscal year.
JYNT has been the topic of a number of research analyst reports. Zacks Investment Research downgraded The Joint Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Roth Capital initiated coverage on The Joint Corp. in a research report on Thursday, July 27th. They set a “buy” rating and a $5.70 target price on the stock. Finally, Maxim Group reiterated a “buy” rating and set a $7.00 target price on shares of The Joint Corp. in a research report on Friday, August 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The Joint Corp. has an average rating of “Buy” and an average price target of $5.86.
The Joint Corp. Company Profile
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.